Knight Therapeutics reported adjusted EPS of C$0.0505, above the C$0.01 estimate. Revenue rose 13%, and management raised its 2026 outlook.
Knight Therapeutics Inc. (TSX: GUD) reported third-quarter 2026 results before markets opened on Nov. 5. Calendar data put EPS at C$0.0505, compared with an estimate of C$0.01—a 405% positive surprise. The company also reported higher revenue and gross margins, and raised its full-year guidance. But the headline beat doesn’t tell the whole story for Canadian investors: Knight still posted an operating loss and a net loss under IFRS.
Recent earnings trend
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$1.12B
P/E
71.4x
52W high
$11.86
52W low
$5.66
1W change
+1.33%
Beta
0.02
Analyst Price Targets
Based on analyst covering GUD · as of Oct 19, 2026
Wall Street analysts forecast GUD stock price to rise 2.0% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.65
+2.0% Upside
Previously C$11.19 on Sep 17, 2026
Current Price
C$11.42
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
23.2%
Annualized
90-Day Vol
26.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$13.65
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$12.12 | C$11.19 – C$13.13 |
| 60 trading days | C$12.86 | C$11.49 – C$14.41 |
| 90 trading days | C$13.65 | C$11.88 – C$15.69 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-05 | 0.0505 | 0.0100 | +405.0% |
| 2026-06-30 | 2026-08-06 | -0.0300 | 0.0300 | -200.0% |
| 2026-03-31 | 2026-05-06 | 0.1389 | 0.0100 | +1289.0% |
| 2025-12-31 | 2026-03-19 | 0.1000 | 0.0100 | +900.0% |
| 2025-09-30 | 2025-11-06 | -0.0100 | 0.0200 | -150.0% |
| 2025-06-30 | 2025-08-07 | -0.0900 | 0.0200 | -550.0% |
Investor takeaway: Knight’s sales and adjusted profitability improved, and management raised its 2026 outlook. Read the EPS surprise carefully: the calendar figure differs from the company’s reported IFRS net loss per share of C$0.03. The key questions are whether promoted products keep growing, margins hold, and pipeline launches turn into sales.
C$137.7 million in Q3 revenue
Revenue rose 13% year over year, and gross margin increased to 50% from 46%. Adjusted revenue was C$136.7 million, up 12% as reported and 4% on a constant-currency basis. Knight said growth in promoted products and stronger Latin American currencies helped, while purchasing patterns at some customers partly offset the gains.
Bull case
Revenue rose 13% year over year to C$137.7 million, and gross margin increased to 50% from 46%. Adjusted EBITDA grew 13% to C$23.8 million. Management also raised its 2026 revenue outlook to C$560 million–C$570 million and expects adjusted EBITDA to reach about 17.5% of revenue. Knight’s C$114.5 million in net cash and its estimate of more than C$300 million in peak annual revenue from pipeline and recently launched products add to the growth case.
Bear case
Despite stronger adjusted results, Knight reported an IFRS operating loss of C$6.6 million and a net loss of C$2.7 million for the quarter. The company said customer purchasing patterns partly offset product growth. Its outlook also depends on regulatory reviews, launches and execution across several markets. Health Canada’s request for more information on Crexont shows the risks involved. A reported P/E of 71.4 and profit margin of 2.84% leave little room for weaker growth or margins.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
